miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.

scientific article published on 17 October 2016

miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12031-016-0851-3
P698PubMed publication ID27752929

P50authorMajid KheirollahiQ64794334
Fariborz KhorvashQ82566876
P2093author name stringNaeim Ehtesham
P2860cites workGlatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosisQ21135220
MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole bloodQ21562182
Multiple sclerosis: Geoepidemiology, genetics and the environmentQ22252524
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Q22252938
KEGG: kyoto encyclopedia of genes and genomesQ24515297
Regulation of type I interferon responsesQ26853177
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesQ27860739
MicroRNAs: genomics, biogenesis, mechanism, and functionQ27861070
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsQ28131785
Mechanisms of type-I- and type-II-interferon-mediated signallingQ28247893
Circulating microRNAs as biomarkers for disease staging in multiple sclerosisQ28287246
MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitisQ28975627
Regulation of mRNA translation and stability by microRNAsQ29547304
Biomarkers in multiple sclerosisQ30978587
Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controlsQ33510154
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosisQ33678267
Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.Q33765140
Beta-interferon for multiple sclerosisQ33843993
Inhibition of cell viability by human IFN-β is mediated by microRNA-431.Q34251002
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialQ34611762
Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-betaQ34700070
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20bQ34994463
MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progressionQ35599410
MicroRNAs and STAT interplay.Q35785559
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosisQ35847422
Multiple sclerosis--the plaque and its pathogenesisQ36410882
miRTarBase 2016: updates to the experimentally validated miRNA-target interactions databaseQ36434925
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosisQ36638670
MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patientsQ37139127
microRNAs and the immune responseQ37178538
Predicting responders to therapies for multiple sclerosisQ37606292
IFN-beta pharmacogenomics in multiple sclerosisQ37780222
Determinants of interferon β efficacy in patients with multiple sclerosisQ37848651
The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models.Q38125129
Regulation of interferon-dependent mRNA translation of target genesQ38190098
miRNA in multiple sclerosis: search for novel biomarkersQ38447020
MiR-126: a novel route for natalizumab action?Q42233577
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.Q46490039
miRWalk2.0: a comprehensive atlas of microRNA-target interactionsQ46692723
MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapyQ47199545
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.Q48301171
Differential microRNA expression in blood in multiple sclerosis.Q50901331
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.Q53383288
Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.Q53566540
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.Q54507185
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.Q54529253
Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapyQ84089706
P433issue1
P921main subjectmultiple sclerosisQ8277
pleiotropyQ1134884
P304page(s)16-24
P577publication date2016-10-17
P1433published inJournal of Molecular NeuroscienceQ15708870
P1476titlemiR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients
P478volume61

Reverse relations

cites work (P2860)
Q92355853Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1
Q89493546Environmental Influencers, MicroRNA, and Multiple Sclerosis
Q92354306Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World

Search more.